| Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis VB Kraus, B Burnett, J Coindreau, S Cottrell, D Eyre, M Gendreau, ... Osteoarthritis and Cartilage 19 (5), 515-542, 2011 | 362 | 2011 |
| Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man S Persiani, E Roda, LC Rovati, M Locatelli, G Giacovelli, A Roda Osteoarthritis and Cartilage 13 (12), 1041-1049, 2005 | 242 | 2005 |
| Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose S Persiani, R Rotini, G Trisolino, LC Rovati, M Locatelli, D Paganini, ... Osteoarthritis and Cartilage 15 (7), 764-772, 2007 | 186 | 2007 |
| Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties LC Rovati, F Girolami, S Persiani Therapeutic advances in musculoskeletal disease 4 (3), 167-180, 2012 | 99 | 2012 |
| OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis VB Kraus, FJ Blanco, M Englund, Y Henrotin, LS Lohmander, E Losina, ... Osteoarthritis and Cartilage 23 (5), 686-697, 2015 | 85 | 2015 |
| Development and validation of a sensitive HPLC–ESI-MS/MS method for the direct determination of glucosamine in human plasma A Roda, L Sabatini, A Barbieri, M Guardigli, M Locatelli, FS Violante, ... Journal of Chromatography B 844 (1), 119-126, 2006 | 79 | 2006 |
| Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in … AC Andreotti, E Pianezzola, S Persiani, MA Pacciarini, M Strolin Benedetti, ... The Journal of Clinical Endocrinology & Metabolism 80 (3), 841-845, 1995 | 72 | 1995 |
| Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers G Fornasini, N Monti, G Brogin, M Gallina, M Eandi, S Persiani, M Bani, ... Chirality 9 (3), 297-302, 1997 | 44 | 1997 |
| Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide F Formelli, E Cavadini, R Luksch, A Garaventa, MG Villani, V Appierto, ... Cancer chemotherapy and pharmacology 62, 655-665, 2008 | 37 | 2008 |
| Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug G Caselli, A Bonazzi, M Lanza, F Ferrari, D Maggioni, C Ferioli, ... Arthritis Research & Therapy 20, 1-19, 2018 | 35 | 2018 |
| Transcellular processing of disulfide‐and thioether‐linked peroxidase‐polylysine conjugates in cultured MDCK epithelial cells J Wan, S Persiani, WC Shen Journal of cellular physiology 145 (1), 9-15, 1990 | 33 | 1990 |
| Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay S Persiani, F Broutin, P Cicioni, P Stefanini, MS Benedetti European journal of pharmaceutical sciences 4 (6), 331-340, 1996 | 31 | 1996 |
| Polylysine conjugates of Bowman–Birk protease inhibitor as targeted anti-carcinogenic agents S Persiani, A Yeung, WC Shen, AR Kennedy Carcinogenesis 12 (6), 1149-1152, 1991 | 31 | 1991 |
| Development and validation of a HPLC–ES-MS/MS method for the determination of glucosamine in human synovial fluid E Pastorini, R Rotini, M Guardigli, S Vecchiotti, S Persiani, G Trisolino, ... Journal of Pharmaceutical and Biomedical Analysis 50 (5), 1009-1014, 2009 | 29 | 2009 |
| Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers S Persiani, G Sassolas, G Piscitelli, CA Bizollon, I Poggesi, E Pianezzola, ... Journal of pharmaceutical sciences 83 (10), 1421-1424, 1994 | 29 | 1994 |
| Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors M Biava, C Battilocchio, G Poce, S Alfonso, S Consalvi, A Di Capua, ... Bioorganic & medicinal chemistry 22 (2), 772-786, 2014 | 28 | 2014 |
| Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake. T Piepoli, T Zanelli, O Letari, S Persiani, LC Rovati, G Caselli ARTHRITIS AND RHEUMATISM 52 (9), S502-S503, 2005 | 28 | 2005 |
| A double‐blind, placebo‐controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor … M Bani, A Colantoni, M Guillaume, F Macchi, G Moroni, S Persiani British journal of clinical pharmacology 50 (4), 338-349, 2000 | 27 | 2000 |
| Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. S Persiani, R Rotini, G Trisolino, L Delliponti, LC Rovati, M Locatelli, ... ARTHRITIS AND RHEUMATISM 52 (9), S508-S508, 2005 | 24 | 2005 |
| Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients S Persiani, M D'Amato, F Makovec, SH Arshad, ST Holgate, LC Rovati Biopharmaceutics & drug disposition 22 (2), 73-81, 2001 | 21 | 2001 |
